Phaseline

Targets › MERTK

MERTK (Tyrosine-protein kinase Mer): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). (UniProt, Q12866)

Open in Phaseline: the race on MERTK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Emory UniversityMRX-2843
FLT3/MerTK inhibitor
FLT3, MERTKPhase 1Advanced Lung Non-Small Cell CarcinomaDec 2026

Conditions

Advanced Lung Non-Small Cell Carcinoma (1)

Modalities

small molecule (1)

Companies

Emory University (1)

Related targets

FLT3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.